# The Cycle of Ineffective Atopic Dermatitis (AD) Treatment

۲

## Mild to Moderate **Moderate to Severe** Mild to Moderate **Moderate to Severe** Allergens Dust mites Staph Allergens **Dust mites** Staph 000 **Incomplete Skin Barrier Integrity Treating the Inflammation Topical steroids** Intermittent topical treatment not effective because the skin barrier is Calcineurin inhibitors not being repaired PDE IV inhibitors

## **Active Treatment**

# **Break the Anti-Inflammatory Cycle – Treat AD with EpiCeram®**

- Epiceram helps maintain a healthy skin barrier to avoid frequency of flares
- Epiceram is ideal for maintaining a healthy skin pH<sup>1</sup>
- Epiceram is effective as monotherapy in mild disease<sup>2\*</sup>
- Epiceram allows for reduction in steroid use<sup>2†</sup>
- Epiceram is shown to have steroid equivalent efficacy<sup>3\*\*</sup>

## References:

1. Kircik L, Hougeir F, Bikowski J. Barrier dysregulation, atopic dermatitis, and the role for a ceramide-dominant, physiologic lipid-based barrier repair emulsion. J Drugs Dermatol. 2013;12(9):611-614.2013.2. Kircik LH, Del Rosso JQ, Aversa D. Evaluating clinical use of a ceramide-dominant, physiologic lipid-based topical emulsion for atopic dermatitis. J Clin Aesth Derm. 2011;4(3):34–40. 3. Sugarman JL, Parish LC. Efficacy of a lipid-based barrier repair formulation in moderate-to severe pediatric atopic dermatitis. J Drugs Dermatol. 2009;8(12):1106-1111. **4.** Kircik L, Hougeir F, Bikowski J. Barrier dysregulation, atopic dermatitis, and the role for a ceramide-dominant, physiologic lipid-based barrier repair emulsion. J Drugs Dermatol. 2013;12(9):611-614. In Press. **5.** Bikowski J. Understanding the structure, function, and strategies for repair of the epidermal barrier. Practical Dermatology. 2009; May:17-18. **6.** Harding CR. The stratum corneum: structure and function in health and disease. Dermatol Ther. 2004;17:6-15.

\* In a clinical study of 207 patients, 70% elected to use EpiCeram®alone with satisfactory results

\*\* EpiCeram® has efficacy to fluticasone as demonstrated in 121 Pediatric Patient Trial \* When used as monotherapy, EpiCeram® can significantly reduce the need for the use of topical steroids for many pediatric patients with moderate-to-severe AD\*\*



# **Failed Maintenance**

( )

## Achieve Optimal Skin Barrier Repair with EpiCeram<sup>®</sup>

۲

## **EpiCeram offers additional benefits to support treatment:**

- An excellent safety profile noncomedogenic<sup>4</sup>
- Provides six times the ceramide level of any other Rx formulation<sup>5</sup>
- Controlled-release BID dosing
- EpiCeram is nonsteroidal; it can be used on patients of any age, anywhere on the skin, and there are no restrictions on long-term use
- The only Rx formulation containing CLA, a fatty acid with PPAR alpha agonist activity (anti-inflammatory)<sup>6</sup>
- Steroid-free, fragrance-free, paraben-free and propylene glycol-free



Available in a 90g tube and 225g airless pump

## **Rx Only** For Topical Dermatological Use Only Product Description

EpiCeram® Controlled Release Skin Barrier Emulsion is a steroid free, fragrance free ceramide dominant emulsion containing ceramide, conjugated linoleic acid (CLA), and cholesterol in an emollient base. These physiological lipids are delivered via a patented time-release system to insure a physiological level over time and maximal performance. The delivery technology is based on a unique proprietary system consisting of multi component microspheres that contain submicron spheres. These submicron spheres are infused with the physiological lipid in an active form and optimal configuration. Rubbing the emulsion onto the skin triggers this two-step delivery system. Once the microsphere is broken the submicron spheres gradually deliver the physiological lipids over time. The special microsphere structure stabilizes the lipids from premature oxidation yielding a product at its highest efficacy

### Indications for Use

EpiCeram® Controlled Release Skin Barrier Emulsion is to be used to treat dry skin conditions and to manage and relieve the burning and riching associated with various types of dematoses, including atopic dematitis, irritant contact dematitis, and radiation dermatitis. EpiCeram<sup>®</sup> helps to relieve dry, waxy skin by maintaining a moist wound and skin environment, which is beneficial to the healing process.

### Contraindications

EpiCeram® Controlled Release Skin Barrier Emulsion is contraindicated in persons with known hypersensitivity to any of the components of the formulation.

### Warnings

EpiCeram® Controlled Release Skin Barrier Emulsion does not contain a sunscreen and should always be used in conjunction with a sunscreen in sun exposed areas. In radiation dermatitis and/or in conjunction with ongoing radiation therapy apply following radiation therapy. Do not apply within 4 hours prior to radiation therapy. Apply twice daily or as indicated by the radiation therapist. After application, a temporary tingling sensation may occur (10 to 15 minutes). Keep this and similar products out of the reach of children. Follow directions for use. If condition does not improve within 10 to 14 days, consult a physician.

## **Precautions and Observations**

For the treatment of any dermal wound, consult a physician.

- Use EpiCeram® Controlled Release Skin Barrier Emulsion only as directed.
  EpiCeram® is non-toxic, however it is for external use only and should not be ingested or taken internally.
- If clinical signs of infection are present, appropriate treatment should be initiated. If clinically
- indicated, use of EpiCeram<sup>®</sup> may be continued during the anti-infective therapy.
- If the condition does not improve within 10-14 days, consult a physician



EpiCeram is a registered trademark of Primus Pharmaceuticals, Inc. Scottsdale, AZ 85253 www.epiceramrx.com

All rights reserved. ISS. 0318 #21014

- EpiCeram<sup>®</sup> does not contain a sunscreen and should always be used in conjunction with a sunscreen in sun exposed areas.
- In radiation dermatitis and/or in conjunction with ongoing radiation therapy. apply following radiation therapy
- Do not apply within 4 hours prior to radiation therapy.
  Apply twice daily or as indicated by the radiation therapist
- Following the application of EpiCeram<sup>®</sup> a temporary tingling sensation may occur (10-15 minutes)
- Keep this and other similar products out of the reach of children.

### Instructions for Use

Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin. If the skin is broken, cover EpiCeram<sup>®</sup> Controlled Release Skin Barrier Emulsion with a dressing of choice.

## Ingredients

Purified Water, MultiSal<sup>™</sup> Neolipids \*, Glyceryl Stearate, Squalane, Glycerin, PEG-100 Stearate, Hydroxypropyl Bispalmitamide MEA (Ceramide), Petrolatum, Dimethicone, Phenoxyethanol, Cholesterol, Conjugated Linoleic Acid, Citric Acid, Palmitic Acid, Xanthan Gum, Potassium Hydroxide, Disodium EDTA, Sorbic Acid, Capric Acid. \* Proprietary microencapsulation system for gradual delivery of key ingredients including Ceramide, CLA, Cholesterol and Palmitic Acid (Formulated with E.Cerifera (Candelilla) wax, corn syrup solids, and modified food starch)

## **How Supplied**

EpiCeram® Controlled Release Skin Barrier Emulsion is supplied as follows: NDC 68040-752-17: 90 gram tube NDC 68040-752-40: 225 gram airless pump NDC 68040-752-38: 100 gram airless pump NDC 68040-752-05: 400g Quad Pack (four 100 gram airless pumps) Store at 15°C to 30°C (59°F to 86°F). Do not freeze. EpiCeram is a registered trademark of Primus Pharmaceuticals, Inc. Scottsdale, AZ 85253 MultiSal is a trademark of Salvona Technologies LLC Made in USA Distributed by: Primus Pharmaceuticals, Inc. Scottsdale, AZ 85253 www.epiceramrx.com



( )